Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human phase I/II study of EIK1003 (IMP1734) in advanced solid tumors
CTR20240637Phase 2Active
- Sponsor
- IMPACT Therapeutics
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of eik1003 in Nonhematologic neoplasms (2 arms), sponsored by IMPACT Therapeutics. Primary endpoints: Treatment-emergent adverse events and dose-limiting toxicities, Maximum tolerated dose and 2 more. Started Mar 2024; status: active.
02
Drugs
eik1003
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20240637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240637.